Synthetic Polymer Patents (Class 424/486)
  • Patent number: 11382731
    Abstract: The present disclosure relates to a medical device and methods of using the same. In embodiments, the medical device may be a buttress formed of nucleophilic buttress components and electrophilic buttress components which react to both form the buttress and provide the buttress with self-sealing capabilities after a staple or some other fixation device is placed therethrough, thereby enhancing its hemostatic properties. In other embodiments, the medical device is a hernia patch formed of a fibrous substrate, nucleophilic precursor components and electrophilic precursor components.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: July 12, 2022
    Assignee: Covidien LP
    Inventors: Walter Skalla, Lauren Vernlund
  • Patent number: 11377268
    Abstract: A sealable container system contains a body and a lid assembly. The body includes an internal volume defined by bottom and side wall(s), bump(s) on the inside surface of the side wall and projecting toward the internal volume, and a lid with outer and inner walls at its bottom side with a channel in-between. A gasket couples to the lid with a wall portion residing within the channel and a lip outside the channel. When the lid assembly is pressed into the body, the lip of the gasket engages the bumps and deforms, and a gap forms between the lip and the side wall, where air in the internal volume exits through the gap. When the lip of the gasket travels past the bumps, the lip fully seats against the inside surface of the side wall, where negative air pressure is imparted to the internal volume of the body.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: July 5, 2022
    Assignee: Zipporo LLC
    Inventors: Leah Naomi, Steven Dibdin, Alaina Appelbaum, Edward Laganis
  • Patent number: 11372041
    Abstract: A measurement of phase frequency response of a device under test (DUT), wherein the DUT is characterized by a set of switchable configurations, comprises choosing the steps of a particular configuration of the DUT having nominal parameters as a reference configuration, measuring an amplitude frequency response Aref (f) and a phase frequency response ?ref(f) of the reference configuration, processing all configurations of the DUT which are different from the reference configuration, one after another, by measuring an amplitude response A(f) of the configuration being processed, calculating a minimum phase difference response ??min(f); and calculating for each configuration, a phase frequency response ?(f) of the respective configuration which is being processed, in accordance with ?(f)=?ref(f)+??min(f).
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: June 28, 2022
    Assignee: Guzik Technical Enterprises
    Inventors: Valeriy Serebryanskiy, Semen P. Volfbein
  • Patent number: 11351116
    Abstract: Methods for forming dermatological compositions that deliver water and/or other hydrophilic compounds into or through the dermis using reverse micelles. The methods include forming compositions with an oil-based continuous phase and an emulsifier that form nanoparticle micelles. The nanoparticle micelles are formulated into biocompatible topical ointments that are stable at room temperature and can be distributed in consumer packaging and consumer distribution channels.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: June 7, 2022
    Inventor: Sean Matthew Anderson
  • Patent number: 11318195
    Abstract: The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine. The RNA may encode a protein of interest, such as a pharmaceutically active protein. Furthermore, the present invention relates to pharmaceutical products, comprising said RNA polyplex formulations for parenteral application to humans or to animals. The present invention relates as well to manufacturing of such pharmaceutical products, comprising, optionally, steps of sterile filtration, freezing and dehydration.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: May 3, 2022
    Assignees: BIONTECH SE, TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
    Inventors: Ugur Sahin, Heinrich Haas, Annette Vogel, Daniel Zucker, Stephanie Erbar, Kerstin Walzer, Anne Schlegel, Sebastian Hörner, Sebastian Kreiter, Mustafa Diken, Jorge Moreno Herrero
  • Patent number: 11311854
    Abstract: The present invention relates to a method for producing biodegradable microspheres having improved safety and storage stability, and a method for producing the same. The present invention provides a method for preparing said biodegradable microspheres while minimizing the morphological changes of microspheres and significantly reducing residual solvents.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: April 26, 2022
    Assignee: G2GBIO, INC.
    Inventors: Heeyong Lee, Eunyoung Seol, Kwonhyeok Yoon
  • Patent number: 11278514
    Abstract: A new use of dunnione compound, a pharmaceutically acceptable salt thereof, a prodrug thereof, a solvate thereof, or an isomer thereof as an effective ingredient for prevention or alleviation of hair loss is disclosed. The dunnione compound, a pharmaceutically acceptable salt thereof, a prodrug thereof, a solvate thereof, or an isomer thereof, in an animal model, showed an effective reduction of hair thinning as well as an effective reduction in loss of hair follicles and inner root sheaths. Thus, the duunione compound, a pharmaceutically acceptable salt thereof, a prodrug thereof, a solvate thereof, or an isomer thereof can be used effectively to treat hair loss and/or loss of hair follicles and inner root sheaths, promoting hair regrowth. The hair loss may be caused by anticancer therapy.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: March 22, 2022
    Assignee: NADIANBIO LTD.
    Inventors: Hong-Seob So, Hyung-Jin Kim, Dipendra Khadka, Gi-Su Oh, Seung-Hoon Lee
  • Patent number: 11273131
    Abstract: Pharmaceutical compositions having enhanced active component permeation properties are described.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: March 15, 2022
    Assignee: AQUESTIVE THERAPEUTICS, INC.
    Inventors: Alexander Mark Schobel, Stephanie Marie Varjan, Stephen Paul Wargacki
  • Patent number: 11267924
    Abstract: Polydiallylamine copolymers are copolymers comprising monomers of polydiallylamine and either polyvinlyamine or polyallylamine. Polydiallylamine copolymers are often crosslinked. The polydiallyamine copolymers are useful as pharmaceutical compositions and may be used in the treatment of type 2 diabetes and for mitigating the complications of type 2 diabetes.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: March 8, 2022
    Assignee: GENZYME CORPORATION
    Inventors: Pradeep K. Dhal, Robert J. Miller, Steven C. Polomoscanik, Philip Just Larsen, Thomas Huebschle, Thorsten Schmidt, Ian Davison, Peter D. McDonnell, Chinyere Agbugba
  • Patent number: 11253395
    Abstract: Systems and methods are provided for generating and applying artificial tear film layers to a cornea surface. An example method includes forming an artificial tear film that is optically transparent, ultra-thin, and smoothly conforming to cornea surface. The artificial tear film includes a lipid layer that prevents evaporation of moisture from the cornea (e.g., from the underlying aqueous layer of the artificial tear film, and/or from the natural tear film on the cornea, etc.). A dispenser, such as an atomizer/nebulizer/micronizer, can be used to generate and applying the artificial tear film layers, especially the lipid layer, with reduced dispensing volume and average droplet size, etc., such that the deposit thickness of the artificial tear film layers remains thin and better spreads and conforms to the surface of the cornea, as compared to the results of conventional eye droppers dispensing conventional artificial tears.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: February 22, 2022
    Assignee: AURORA TEARS TECHNOLOGY, INC.
    Inventor: Ping Cerina Zhang
  • Patent number: 11246842
    Abstract: The invention provides pharmaceutical compositions comprising a dry medicament. The dry medicaments can be rapidly dissolved, solubilized, and/or reconstituted to deliver to a subject. The present invention provides methods of preparing a medical solution. The medical solution can be prepared from mixing the pharmaceutical composition as described herein with a first liquid.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 15, 2022
    Assignee: Windgap Medical, Inc.
    Inventors: Adam R. Standley, Kaliappanadar Nellaiappan, Brent A. Buchine
  • Patent number: 11246945
    Abstract: Disclosed herein is a method for treating a cancer, the method includes following operations. A pharmaceutical composition is administered to a subject in need. The pharmaceutical composition includes a medium and a plurality of cisplatin-loaded microbubbles dispersed in the medium. Each cisplatin-loaded microbubble includes a shell portion and a core portion. The shell portion includes a plurality of albumin molecules and a plurality of first cisplatin molecules covalently bonding to the albumin molecules. The core portion is surrounded by the shell portion, wherein the core portion includes a mixture of inert gas and a plurality of second cisplatin molecules. Ultrasound energy is then applied to a tumor of the subject to break the cisplatin-loaded microbubbles.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: February 15, 2022
    Inventors: Chih-Hung Wang, Ai-Ho Liao, Hang-Kang Chen
  • Patent number: 11213490
    Abstract: The present disclosure provides a delivery system for controlled protein release without encapsulation. Identical, burst-free, extended release profiles for three different protein therapeutics were obtained with and without encapsulation in PLGA nanoparticles embedded within a hydrogel. Using both positively and negatively charged proteins, it was shown that short-range electrostatic interactions between the proteins and the PLGA nanoparticles are the underlying mechanism for controlled release. Moreover, tunable release was demonstrated by modifying nanoparticle concentration, nanoparticle size, or environmental pH. Additionally, the utility of this system was demonstrated in vivo for BDNF delivery in a rat model of stroke. These new insights obviate the need for encapsulation and offer promising, translatable strategies for more effective delivery of therapeutic biomolecules.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: January 4, 2022
    Inventor: Molly Shoichet
  • Patent number: 11213545
    Abstract: Methods are disclosed for inhibiting esophageal inflammation in a subject, that include administering to the esophagus of the subject with esophageal inflammation a therapeutically effective amount of an extracellular matrix (ECM) hydrogel. Methods are also disclosed for reducing esophageal stricture. Compositions are disclosed that include an esophageal extracellular matrix (ECM) hydrogel.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: January 4, 2022
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Stephen Francis Badylak, Juan Diego Naranjo Gutierrez, Lindsey Tamiko Saldin
  • Patent number: 11191761
    Abstract: Disclosed is an SOMCL-9112 solid dispersion. The SOMCL-9112 solid dispersion is characterized by being prepared from the following raw materials in percentage by weight: 5 percent to 60 percent of SOMCL-9112, 5 percent to 90 percent of pharmaceutically acceptable matrix polymer, 0 percent to 20 percent of surfactant, 0 percent to 20 percent of flow aid and 0 percent to 20 percent of plasticizer. Also disclosed are a preparation method of the SOMCL-9112 solid dispersion, a solid medicinal preparation containing the solid dispersion and application of the solid dispersion for preparing a medicine for treating cancer.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: December 7, 2021
    Assignees: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, SHANGHAI ACEBRIGHT PHARMACEUTICALS CO., LTD.
    Inventors: Shiyan Guo, Yong Gan, Ao Zhang, Zehong Miao, Li Gao, Jian Ding
  • Patent number: 11185544
    Abstract: This disclosure provides, among other things, compositions comprising quantities of oltipraz crystals, as well as method of making such compositions, and method of treating patients using such compositions. Taste-modified compositions also are provided.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: November 30, 2021
    Assignee: ST IP Holding AG
    Inventors: Anthony Chris Garland, Barbara-Jean Anne Bormann-Kennedy, Bomi Framroze, Bret Berner, Michael Edward Grass, Casey Keith Jager, Corey Jay Bloom, Mark Joseph Kastantin, Romain Bachelard
  • Patent number: 11185609
    Abstract: A cell growth inhibiting polymer for use in an ophthalmic implant includes at least one cell growth inhibiting monomer; and at least one other monomer selected from an acrylic monomer, a hydrophobic acrylic monomer, a hydrophilic acrylic monomer, a silicone monomer, a vinyl monomer and/or a collagen monomer.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: November 30, 2021
    Assignee: Keramed, Inc.
    Inventor: Yichieh Shiuey
  • Patent number: 11179330
    Abstract: The present invention provides an oral transmucosal film or patch for delivering doxepin through the buccal mucosa or sublingual mucosa. The film or patch is a bilayer structure containing a mucoadhesive layer with amorphous doxepin and soluble backing layer without doxepin. The film or patch has satisfactory bioavailability and improved palatability. The mucoadhesive layer comprises 0.5-25% (w/w) of doxepin, 50-96% of one or more film-forming agents, 1-30% (w/w) of one or more adhesives, and 0.05-5% (w/v) of one or more stabilizers. The backing layer comprises 80-100% (w/w) of one or more film-forming agents. Preferred adhesives include povidone, carbomer, and polycarbophil. Preferred stabilizers include butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), citric acid, and ascorbic acid.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: November 23, 2021
    Assignee: Xiamen LP Pharmaceutical Co., Ltd.
    Inventors: Liyan Xie, Yuantao Song, Shengkai Cao, Zhoue Gao, Rongbin Ling
  • Patent number: 11174507
    Abstract: Labeled probes, and methods of use thereof, comprise a Cas polypeptide conjugated to gRNA that is specific for target nucleic acid sequences, including genomic DNA sequences. The probes and methods can be used to label nucleic acid sequences without global DNA denaturation.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: November 16, 2021
    Assignee: HOWARD HUGHES MEDICAL INSTITUTE
    Inventors: Robert Singer, Timothee Lionnet, Wulan Deng
  • Patent number: 11168412
    Abstract: This invention describes a modified electrospinning method for making uniformly patterned and porous nanofibrous scaffolds that can be utilized in a variety of applications. While traditional electrospinning method uses a foil collector that generates compact layers of nanofibrous structures, resulting on the superficial cell growth and differentiation, the present method comprises adopting additional patterned film(s) on top of the conventional collector to make a patterned porous structure of nanofibrous scaffolds that are capable of supporting cell growth. For example, the method uses a double layered collector composed of a water soluble stabilizer film mounted on a foil to make a uniformly patterned and porous nanofibrous membrane sheets, which enhance both cell growth and attachment.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: November 9, 2021
    Inventors: Dong Jin Lim, Jeremy Vines
  • Patent number: 11162940
    Abstract: Provided is at least one method of suppressing, in an immunoassay using surface plasmon-field enhanced fluorescence spectroscopy (SPFS), nonspecific signals generated by nonspecific adsorption of contaminants contained in a sample to an SPFS sensor section (e.g., a primary antibody, a solid-phase layer and a metal thin film). At least one method relates to a method of suppressing nonspecific signals originating from contaminants in an immunoassay using surface plasmon-field enhanced fluorescence spectroscopy (SPFS) (including cases where a receptor for a compound to be measured is used in place of a primary antibody), the method comprising performing at least one pretreatment.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: November 2, 2021
    Assignee: KONICA MINOLTA, INC.
    Inventors: Tomonori Kaneko, Takeshi Isoda
  • Patent number: 11154637
    Abstract: A biodegradable sealant includes: a polyethylene glycol derivative; a photoinitiator; and a solvent, wherein the content of the polyethylene glycol derivative is about 10-75 wt % in the biodegradable sealant. The polyethylene glycol derivative is obtained by a substitution reaction, and in the substitution reaction, the polyethylene glycol is modified with methacrylic anhydride.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: October 26, 2021
    Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Hsin-Hsin Shen, Yu-Chi Wang, Sen-Lu Chen, Yu-Bing Liou, Jian-Wei Lin, Yi-Hsuan Lee, Ming-Chia Yang, Ying-Wen Shen, Wei-Lin Yu
  • Patent number: 11142747
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: October 12, 2021
    Assignee: Orbsen Therapeutics Limited
    Inventor: Stephen J. Elliman
  • Patent number: 11110066
    Abstract: An implantable delivery device and method for utilizing the device to delivery a bioactive agent to a subject in need thereof is described. The device includes a pattern of structures fabricated on a surface of the device to form a nanotopography. A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. The device may be located adjacent tissue such as an endovascular implant or a perivascular implant, and may deliver the bioactive agent without triggering an immune or foreign body response to the bioactive agent.
    Type: Grant
    Filed: October 16, 2012
    Date of Patent: September 7, 2021
    Assignee: SORRENTO THERAPEUTICS, INC.
    Inventors: Jeremy Ollerenshaw, Emily Reichart, Russell F. Ross
  • Patent number: 11110175
    Abstract: The present invention provides compositions and methods for delivery of therapeutic agents across an barrier. The compositions include a therapeutic agent (e.g., antimicrobial agent, antibiotic, or anesthetic agent), a permeation enhancer which increases the flux of the therapeutic agent across the barrier, and a matrix forming agent. The matrix forming agent forms a gel at a suitable gelation temperature and rheological properties for use in drug delivery, and in some cases, the gelation temperature and rheological properties are not significantly changed from those of the composition without the permeation enhancer. The invention also provides a matrix forming agent and compositions thereof. Such compositions are particularly useful in the treatment of otitis media. Methods of treatment, methods of delivery, and kits for the compositions described herein are also provided.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: September 7, 2021
    Assignees: Children's Medical Center Corporation, Massachusetts Institute of Technology
    Inventors: Daniel S. Kohane, Rong Yang, Lily Yun Lin
  • Patent number: 11096882
    Abstract: The present disclosure relates to anhydrous cosmetic compositions which contain a combination of a strongly swelling and a low-swelling water-absorbing component, an odor-absorbing component and a deodorant active ingredient. These compositions have an outstanding deodorizing effect and improved sensory features and additionally result in a minimization of sweat spots on textiles. Furthermore, the present disclosure relates to a cosmetic product containing these anhydrous compositions and the use of this composition or product for reduction of the body odor released by perspiration. Finally, the present disclosure relates to the use a strongly swelling water-absorbing component in combination with an odor-absorbing component to improve the sensory characteristics of anhydrous deodorant compositions.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: August 24, 2021
    Assignee: Henkel AG & Co. KGaA
    Inventors: Bernhard Banowski, Marcus Claas, Angela Mueller
  • Patent number: 11083821
    Abstract: Provided herein are biocompatible hydrogel polymers capable of gelling in vivo comprising a therapeutic agent such as a protein or other biomolecule and kits comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and at least one therapeutic agent. The biocompatible hydrogel polymer is bioabsorbable and releases the therapeutic agent at a target site, avoiding systemic exposure and achieving a controlled delivery.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: August 10, 2021
    Assignee: C.P. Medical Corporation
    Inventors: Syed H. Askari, Yeon S. Choi, George Horng
  • Patent number: 11078248
    Abstract: The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors. The invention further relates to compositions including a protease and a growth factor comprising a bone morphogenic protein (BMP) or a variant thereof. The invention also relates to methods of using the composition.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: August 3, 2021
    Assignee: LifeNet Health
    Inventors: Xiaofei Qin, Silvia Chen, Jingsong Chen, James Clagett
  • Patent number: 11077056
    Abstract: Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: August 3, 2021
    Assignees: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Andrew Bellinger, Shiyi Zhang, Carlo Giovanni Traverso, Robert S. Langer, Stacy Mo, Tyler Grant, Mousa Jafari, Dean Liang Glettig, Angela DiCiccio, Lowell L. Wood, Jr., Philip A. Eckhoff
  • Patent number: 11058532
    Abstract: A composite scaffold having a highly porous interior with increased surface area and void volume is surrounded by a flexible support structure that substantially maintains its three-dimensional shape under tension and provides mechanical reinforcement during repair or reconstruction of soft tissue while simultaneously facilitating regeneration of functional tissue.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: July 13, 2021
    Assignee: Biorez, Inc.
    Inventors: Kevin A. Rocco, Bhavana Mohanraj, Jeffrey Ott, Justin Bendigo, Jacob Edward Komenda, Mark Theodore Aronson, Andrew James Carter
  • Patent number: 11058684
    Abstract: The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: July 13, 2021
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
    Inventors: Ajay Jaysingh Khopade, Arindam Halder
  • Patent number: 11059960
    Abstract: A flame retardant composition and a method of making a flame retardant composition is provided. In an embodiment, the method includes reacting a phosphazene material with an acrylamide monomer material to form a functionalized phosphazene material; initiating a polymerization reaction on a reaction mixture comprising a functionalized phosphazene material and one or more monomers to form a first impact-modified phosphazene material; and reacting the first impact-modified phosphazene material with a poly(dichlorophosphazene) monomer material, and a reactant selected from the group consisting of R1OH, HNR2R3, or a combination thereof, to form a second impact-modified phosphazene material.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: July 13, 2021
    Assignee: International Business Machines Corporation
    Inventors: Brandon M. Kobilka, Joseph Kuczynski, Jacob T. Porter, Jason T. Wertz
  • Patent number: 11045435
    Abstract: The present invention is related to a method for treating an ocular disease, particularly a diabetes related ocular disease, comprising administering to a subject in need thereof an effective amount of a group of compounds having a structure of Formula A1, wherein the ocular disease is selected from the group consisting of proliferative vitreoretinopathy (PVR), uveitis, glaucoma and age related macular degeneration (AMD), and the diabetes related ocular disease is selected from the group consisting of diabetic retinopathy (DR) and diabetic macular edema (DME).
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: June 29, 2021
    Assignee: NATUREWISE BIOTECH & MEDICALS CORPORATION
    Inventors: George Chung-Yih Chiou, Chia-Nan Chen
  • Patent number: 11019902
    Abstract: The present disclosure relates to, inter alia, a green technology for crosslinking protein molecules for various uses, where the protein molecules can be contained in protein fibers such as, but not limited to, human hair, animal fibers, and mixtures thereof. In one aspect, the present disclosure relates to a crosslinking agent comprising an oxidized sugar having at least two aldehyde groups. In another aspect, the present disclosure relates to a method of crosslinking protein fibers. This method involves providing the aforementioned crosslinking agent and infiltrating a plurality of non-crosslinked protein fibers with the crosslinking agent under conditions effective to cause protein molecules contained in the non-crosslinked protein fibers to become crosslinked, thereby yielding a population of crosslinked protein fibers.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: June 1, 2021
    Assignee: CORNELL UNIVERSITY
    Inventors: Anil Netravali, Yidong Zhong
  • Patent number: 11021580
    Abstract: A process for manufacturing a cross-linked hyaluronic acid (HA) gel product is comprising the steps of: (a) preparing an aqueous mixture of HA and a cross-linking agent selected from multiepoxides and diepoxides; wherein the HA is dissolved in an aqueous solution containing 1-10% (w/w) inorganic hydroxide; and wherein the dissolved HA constitutes more than 10% (w/w) of the final mixture; and (b) subjecting the aqueous mixture to cross-linking conditions to allow the dissolved HA to react with the cross-linking agent so as to obtain a cross-linked HA gel product.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: June 1, 2021
    Assignee: Galderma Holding SA
    Inventor: Morgan Karlsson
  • Patent number: 11013809
    Abstract: The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating to delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become a solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite or a prodrug thereof.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: May 25, 2021
    Assignee: INDIVIOR UK Limited
    Inventors: Eric Dadey, Qi Li, Christopher Lindemann
  • Patent number: 10993907
    Abstract: The present invention relates to a pharmaceutical formulation for vaginal administration, wherein the formulation comprises a pharmaceutical acceptable excipient and glucono ?-lactone, wherein the glucono ?-lactone is present in an amount of 5 to 99 wt % of the formulation. The invention also relates to a pharmaceutical formulation according to the invention for use in the prevention or treatment of a urogenital fungal infection. Furthermore, the invention relates to glucono ?-lactone (formula (III)), for use in the in the prevention or treatment of a fungal infection.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: May 4, 2021
    Assignee: Gedea Biotech AB
    Inventors: Ulf Ellervik, Olov Sterner, Helena Strevens, Sophie Manner
  • Patent number: 10987306
    Abstract: The present invention provides a pH dependent vaginal composition delivering a therapeutically effective amount of at least one active essentially at a pH above 4.5. The composition provides a diagnostic visual pH indication of the presence of vulvovaginitis at pH above 4.5. In the absence of such indication, the treatment may be discontinued. Another visual signal is the retrieval of the unchanged composition, which also points to a normal pH at or below 4.5 and absence of vulvovaginitis.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: April 27, 2021
    Assignee: Eve Pharma Ltd.
    Inventors: Eran Eilat, Stephen Cherkez
  • Patent number: 10980913
    Abstract: The present invention is directed to tissue sealant compositions comprising: a multi-arm reactive polyethylene glycol polymer having at least 3 electrophilic groups; albumin; a buffer; water; and entrained gas as bubbles; wherein concentration of albumin in a liquid component of the sealant is within range of 50-200 mg/ml; and wherein concentration of multi-arm PEG in said liquid component of the sealant is within range of 25-100 mg/mL.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: April 20, 2021
    Assignee: Ethicon LLC
    Inventors: Sridevi N. Dhanaraj, Nir I. Nativ, Ashley DeAnglis
  • Patent number: 10967039
    Abstract: A process for the preparation of targeting nanoparticles of a poly(alkyl cyanoacrylate) homopolymer or copolymer, wherein said method comprises, in a single step, the anionic polymerisation of an oil-in-water miniemulsion as herein defined. The invention also relates to nanoparticles produced from said process and to their use in medicine.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: April 6, 2021
    Assignee: SINTEF TTO AS
    Inventors: Ruth Schmid, Per Stenstad, Yrr Morch, Heidi Johnsen
  • Patent number: 10968292
    Abstract: A synthetic polymer film is a synthetic polymer film whose surface has a plurality of raised or recessed portions. The synthetic polymer film has a crosslink structure, and the crosslink structure does not contain any nitrogen element that is a constituent of a urethane bond. The synthetic polymer film contains an organic carboxylic acid, and an amount of water required for dissolving 1 g of the organic carboxylic acid is equal to or greater than 10 mL and less than 10000 mL. At the lapse of 5 minutes since placing a 200 ?L drop of water on the surface of the synthetic polymer film, a pH of an aqueous solution is not more than 5, and an area equivalent circle diameter of the aqueous solution is not less than 20 mm. A synthetic polymer film whose surface has a microbicidal activity can be produced using a photocurable resin composition which contains an organic carboxylic acid or a photoacid generator which generates the organic carboxylic acid.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: April 6, 2021
    Assignee: SHARP KABUSHIKI KAISHA
    Inventors: Yasuhiro Shibai, Miho Yamada, Ken Atsumo, Kiyoshi Minoura
  • Patent number: 10952981
    Abstract: The present invention relates to liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable liquid pharmaceutical compositions of baclofen at concentrations of 5 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions are suitable for oral administration, and stable at pH ranges of 5-8 over a variety of storage conditions, including long-term storage for extended periods of time.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: March 23, 2021
    Assignee: SLAYBACK PHARMA LLC
    Inventors: Sushant Omprakash Dube, Girish Kumar Jain, Venkateshwar Reddy Keesara, Josh Chandy Mathew, Purushottam Dattatraya Kulkarni, Purushottam Sakhahari Pattewar, Balakrishna Reddy Akula, Kumarswamy Ummiti
  • Patent number: 10955321
    Abstract: Disclosed is a biological sample collector 500 comprising a solid support 12 having plural discrete areas (22, 24, 26, 28 FIG. 1) for accepting a biological sample, each area being chemically differentiated, for example by having a different chemical treatment sorbed onto the solid support. An envelope 530 encloses the solid support. A cover portion 520 can cover the biological sample after collection to prevent infection. UV light can be applied to the collected sample to reduce the risk of infection.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: March 23, 2021
    Assignee: Global Life Sciences Solutions Operations UK Ltd
    Inventors: Peter James Tatnell, Jeffrey Kenneth Horton, Christopher George Norey, Alan Stuart Pierce, Robert John
  • Patent number: 10933028
    Abstract: The invention discloses a preparation method of pH/reduction responsive polyamino acid zwitterionic nanoparticles, which belongs to the technical field of polymer synthesis and biomedical materials. In the invention aliphatic amines are used to initiate ring-opening polymerization of ?-benzyl-L-glutamate-N-carboxylic anhydride, and the obtained poly(?-benzyl-L-glutamate) reacts with L-lysine to form azwitterionic polymer. The zwitterionic polymer is crosslinked by cysteamine, producing pH/reduction responsive polyamino acid zwitterionic nanoparticles after purification. The nanoparticles are pH responsive and resistant to non-specific protein adsorption. Because cysteamine contains disulfide bonds, the nanoparticles have sensitive reductive responsiveness and can load anticancer drugs for controlled release at the target site of cancer.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: March 2, 2021
    Assignee: JIANGNAN UNIVERSITY
    Inventors: Liping Zhang, Caihua Ni, Ren Liu, Dawei Wang, Gang Shi, Xinxin Sang, Xiaofeng Xia
  • Patent number: 10933011
    Abstract: A composition comprises (A) a silicone elastomer. The (A) silicone elastomer comprises the reaction product of: (a) an organohydrogensiloxane having an average of at least two silicon-bonded hydrogen atoms per molecule; (b) a crosslinking agent having an average of at least two ethylenically unsaturated groups per molecule; and (c) a hydrosilylation catalyst. The reaction product is formed in the in the presence of (d) a silicone polyether polymer; and (e) particles. The composition further comprises (B) a carrier fluid. The (e) particles are dispersed in the (A) silicone elastomer in the composition. A method of preparing the composition is also disclosed.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: March 2, 2021
    Assignee: Dow Silicones Corporation
    Inventors: Zhi Li, Bartley D. Maxon, Kimmai T. Nguyen, Paul W. Pretzer, Kristen E. Steinbrecher, Lisa M. Vanommeren, Evan Waddell, Fang Zhang, Kenneth E. Zimmerman
  • Patent number: 10933024
    Abstract: The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising at least one pharmaceutical active ingredient, with the exception of opioids, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer comprises a polymer mixture of i) 40-95% by weight, based on dry weight of the polymer mixture, of at least one water insoluble essentially neutral vinyl polymer or copolymer, and ii) 5-60% by weight, based on dry weight of the polymer mixture, of at least one anionic polymer or copolymer, which is insoluble in a buffered medium below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0, characterized in that the coating layer further comprises 110 to 250% by weight of a non-porous inert lubricant, 1 to 35% by weight of at least one neutral cellulosic compound and 1 to 25% by weight of at least one emulsifier, each calculated on dry weight of the polymer mixture.
    Type: Grant
    Filed: September 24, 2008
    Date of Patent: March 2, 2021
    Assignee: Evonik Operations GmbH
    Inventors: Hans Baer, Thomas Fuerst, Gerhard Renner, Michael Gottschalk
  • Patent number: 10869905
    Abstract: In a composition and a microneedle for a localized obesity treatment containing the same in accordance with the present disclosure, the composition in accordance with the present disclosure contains a gelatin, decomposes a fat in a body, and inhibits lipogenesis and fat deposition in the body.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: December 22, 2020
    Assignee: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION
    Inventors: Seung Yun Yang, Beum Soo An, Keum Yong Seong, Sung Min An
  • Patent number: 10858491
    Abstract: The present invention provides porous particles made of an organic polymer, uniform in shape, and having through holes that are not closed. The porous particles according to the present invention are porous particles having a substantially spherical shape. The porous particles are made of an organic polymer. Each of the porous particles has an interconnected pore structure in which through holes provided inside the porous particle communicate with each other, and ends of the through holes are open toward an outside of the porous particle.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: December 8, 2020
    Assignees: Kyoto University, Emaus Kyoto, Inc., Kosen National Institute of Technology
    Inventors: Norio Ishizuka, Kyoko Konishi, Toshikazu Oda, Yoshinobu Tsujii, Keita Sakakibara, Takaya Sato
  • Patent number: 10842969
    Abstract: Systems, devices, and methods for maintaining patency in a bronchus of a patient are presented. A catheter is positioned within the bronchus. A target region of one or more of a bronchial wall, submucosa, media, and adventitia is punctured with an injection needle disposed on a distal end of the catheter. Such puncturing is achieved by expanding a balloon disposed on the distal end of the catheter. The balloon may be comprised of at least two materials of different elastic modulus, which allows for a flexible but relatively non-distensible, unfolding component of the balloon as well as an elastomeric, inflatable component of the balloon. Through the injection needle, an amount of one or more crosslinking agents is delivered to the target region. The delivered amount is effective to provide structural support for the bronchial wall, substituting for the bronchial cartilage thereby treating bronchomalacia.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: November 24, 2020
    Assignee: MERCATOR MEDSYSTEMS, INC.
    Inventor: Kirk Patrick Seward
  • Patent number: 10828258
    Abstract: The present invention relates to a directly compressible composition for the production of tablets which comprise fine-grained polyvinyl alcohols (PVAs) and fine-grained microcrystalline celluloses (MCCs) in a co-mixture. The present invention also relates to the use of this mixture and to a process for the preparation thereof.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: November 10, 2020
    Assignee: Merck Patent GmbH
    Inventors: Roberto Ognibene, Finn Bauer, Thorsten Wedel, Guenter Moddelmog